Short acting GLP-1 receptor agonist (injectable)

Lixisenatide 5 µg injection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

LIXI_SC_5UG_OTHER

Mechanism: GLP-1 receptor agonist; exenatide twice daily and lixisenatide (half life about 2 to 4 hours); beinaglutide (recombinant human GLP-1; half life of minutes)
Trials: 0
Participants in these arms: 0

All doses pooled: Lixisenatide injection
Lixisenatide 20 ug subcutaneous once daily
Lixisenatide 5 µg injection once daily
Lixisenatide 10 µg injection once daily
Lixisenatide 30 µg injection once daily
Lixisenatide 5 µg injection twice daily
Lixisenatide 10 µg injection twice daily
Lixisenatide 20 µg injection twice daily
Lixisenatide 30 µg injection twice daily
Lixisenatide 10 µg injection
Lixisenatide 2.5 µg injection
Lixisenatide 20 µg injection

Lixisenatide 5 µg injection

Related

Trials